Politics

Firm Linked to Trump’s Sons Got Nearly $40 Million in Federal Contracts to Screen for Ebola and Other Diseases

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 09/11/2026, 11:24:25 UTC.

Briefings

The Trump administration awarded XpresTest, a biosecurity firm linked to Donald Trump Jr. and Eric Trump, nearly $40 million in contracts to screen for Ebola and other diseases. XpresTest previously earned most revenue from spa treatments at U.S. airports. The contracts are seven times larger than previous government deals for the company. The Democratic Republic of Congo outbreak has killed over 5,000 people this year, making the deals high stakes. XpresTest CEO Ezra Ernst admitted the work is new and expressed uncertainty about completing it in the DRC. The Trump sons are described as passive minority investors with no involvement in contract negotiation. The State Department awarded $20 million to XpresTest under a new global health strategy, while the CDC awarded $18.8 million. The Trump family spokesperson stated they have no knowledge regarding the contracts.

Key points

• XpresTest received nearly $40 million in contracts to screen for Ebola and other diseases, seven times its previous total government contract value.
• The Trump sons are described as passive minority investors with no involvement in contract negotiation, according to their spokesperson.

Context

XpresTest, a hybrid company selling spa treatments and biosecurity services, previously earned most revenue from airport spas. The contracts are the latest example of the Trump family benefiting financially from the administration's actions, occurring just months after a firm linked to the Trumps invested in its parent company. The stakes are high due to an ongoing Ebola outbreak in the Democratic Republic of Congo that has killed over 5,000 people this year.

Limitations

The evidence is limited to a single article from November 2026. The Trump sons' specific stake size in XWELL is stated as more than 10% but no exact figure is provided. The State Department and CDC did not respond to requests for comment. XpresTest's CEO expressed uncertainty about completing work in the volatile DRC, and the article does not provide details on the competitive bidding process or the specific criteria used to select the firm.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 09/11/2026, 12:54:25 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihaomulu74cduk4qznmwdvh2vp4kbzt6ayhuhqcxnyuzgqpotka5e